Search
forLearn
5 / 801 resultslearn Ceramide EOP
learn Pantothenyl ethylether
learn procapil
learn Eicosapentaoenoic acid
Research
5 / 1000+ results
research Bioactive antiinflammatory antibacterial hemostatic citrate-based dressing with macrophage polarization regulation for accelerating wound healing and hair follicle neogenesis
A special dressing called FEA-PCEI can speed up wound healing, reduce scars, and help grow new hair follicles, but only at the right dosage.
research Alginate-Based Cryogels for Combined Chemo/Photothermal Antibacterial Therapy and Rapid Hemostasis
SEF cryogels effectively kill bacteria, stop bleeding, and speed up wound healing.
research Biomechanics of hair fibre growth: A multi-scale modeling approach
The model shows that factors like follicle shape and stiffness are key for hair growth and anchoring.
research Anti-Alopecia Activity of Alkaloids Group from Noni Fruit against Dihydrotestosterone-Induced Male Rabbits and Its Molecular Mechanism: In Vivo and In Silico Studies
Noni fruit extract, specifically the FEA-3 sub-fraction, can increase hair growth and reduce baldness in male rabbits, potentially acting like common hair loss treatments.
research 5α-reductase inhibition and hair growth promotion of some Thai plants traditionally used for hair treatment
Some Thai plants, especially Carthamus tinctorius, could help prevent hair loss and promote hair growth without adverse effects.
Community Join
5 / 1000+ resultscommunity Why is there no feedback on pge2/setipiprant?
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
community Track hairline of Pelage executives
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.